Research

Hormonal

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces the prevalence of metabolic syndrome by improving its core components: glycemic control, body weight, lipid profiles, and blood pressure.

If you have metabolic syndrome (high blood pressure, high blood sugar, high cholesterol, and excess belly fat), talk to your doctor about tirzepatide. It is a once-weekly injection that helps lower blood sugar, reduce weight, improve cholesterol, and lower blood pressure. While it can cause temporary stomach issues, these often go away, and it may offer a more comprehensive solution than lifestyle changes alone.

GoodSupportsHIGH confidence
Evidence from the SURPASS clinical program and the SURMOUNT-1 trial demonstrates tirzepatide’s robust effects on several metabolic parameters. It has been shown to significantly reduce HbA1c levels, promote substantial and dose-dependent weight loss, improve lipid profiles, and lower blood pressure.
Sylwia Tomasiczek et al. · International Journal of Innovative Technologies in Social Science · 2025

Why this rating

Based on post-hoc analyses of robust Phase 3 clinical trials (SURPASS and SURMOUNT-1), which are high-quality evidence, though metabolic syndrome was not the primary endpoint.

Source

ONE DRUG TO FIX IT ALL? THE ROLE OF TIRZEPATIDE IN TREATING COMPONENTS OF METABOLIC SYNDROME

Sylwia Tomasiczek et al. · International Journal of Innovative Technologies in Social Science · 2025

DOI 10.31435/ijitss.4(48).2025.4180

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →